TickerFacts.

Compare

Iovance Biotherapeutics, Inc. vs Vericel Corp vs Adaptive Biotechnologies Corp vs Twist Bioscience Corp

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearIovance Biotherapeutics, Inc.
IOVA		Vericel Corp
VCEL		Adaptive Biotechnologies Corp
ADPT		Twist Bioscience Corp
TWST
Year ended2025-12-312025-12-312025-12-312025-09-30
Revenue$263.50M$276.26M$276.98M$376.57M
Revenue growth (YoY)+60.6%+16.5%+54.8%+20.3%
Gross margin34.3% (computed)74.4% (computed)74.2% (computed)50.7% (computed)
Operating margin-153.1%4.0%-20.6%-36.2%
Net margin-148.4%6.0%-21.5%-20.6%
Net income-$390.98M$16.52M-$59.50M-$77.67M
EPS (Diluted)-$1.09$0.32-$0.39-$1.30
Operating cash flow-$302.41M$51.91M-$45.99M-$47.63M
Free cash flow-$336.24M$24.75M-$48.95M-$75.63M
Cash & equivalents$163.08M$100.09M$70.50M$183.05M
Total assets$913.17M$487.97M$512.74M$641.86M
Total liabilities$214.59M$133.33M$287.74M$168.90M
Shareholders' equity$698.58M$354.64M$218.79M$472.96M
Return on year-end equity-56.0%4.7%-27.2%-16.4%
Shares outstanding411.94M50.62M153.78M60.63M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearIovance Biotherapeutics, Inc.Vericel CorpAdaptive Biotechnologies CorpTwist Bioscience Corp
Latest$263.50M
Ended 2025-12-31		$276.26M
Ended 2025-12-31		$276.98M
Ended 2025-12-31		$376.57M
Ended 2025-09-30
1 year earlier$164.07M
Ended 2024-12-31		$237.22M
Ended 2024-12-31		$178.96M
Ended 2024-12-31		$312.97M
Ended 2024-09-30
2 years earlier$1.19M
Ended 2023-12-31		$197.52M
Ended 2023-12-31		$170.28M
Ended 2023-12-31		$245.11M
Ended 2023-09-30
3 years earliern/a$163.70M
Ended 2022-12-31		$185.31M
Ended 2022-12-31		$203.56M
Ended 2022-09-30
4 years earliern/a$153.07M
Ended 2021-12-31		$154.34M
Ended 2021-12-31		$132.33M
Ended 2021-09-30